The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
25654260 |
49 |
Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approach. |
F. Hoffmann-La Roche |
25642985 |
45 |
Selective nonpeptidic fluorescent ligands for oxytocin receptor: design, synthesis, and application to time-resolved FRET binding assay. |
University of Strasburg |
24874785 |
333 |
New, potent, and selective peptidic oxytocin receptor agonists. |
Ferring Research Institute |
16250654 |
41 |
2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics. |
Glaxosmithkline |
21700453 |
56 |
Optimisation of pharmacokinetic properties to afford an orally bioavailable and selective V1A receptor antagonist. |
Msd |
21458261 |
55 |
The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonists. |
Msd |
21146408 |
53 |
The characterization of a novel V1b antagonist lead series. |
Glaxosmithkline |
20674355 |
58 |
Pyrrolo[1,2-a]pyrazine and pyrazolo[1,5-a]pyrazine: novel, potent, and selective series of Vasopressin 1b receptor antagonists. |
Glaxosmithkline |
19081251 |
38 |
Discovery and optimisation of a potent and selective tertiary sulfonamide oxytocin antagonist. |
Glaxosmithkline |
22984902 |
59 |
Selective fluorescent nonpeptidic antagonists for vasopressin V2 GPCR: application to ligand screening and oligomerization assays. |
University of Strasburg |
22239250 |
59 |
Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency. |
Glaxosmithkline |
22425346 |
28 |
Synthesis and evaluation of C-11, F-18 and I-125 small molecule radioligands for detecting oxytocin receptors. |
Emory University |
19800231 |
92 |
Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists. |
Schering-Plough Research Institute |
18032036 |
17 |
The discovery of GSK221149A: a potent and selective oxytocin antagonist. |
Glaxosmithkline |
17850055 |
18 |
Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. |
Institute Genomics Functional (Igf) |
16302826 |
129 |
Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists. |
Serono Pharmaceutical Research Institute |
15084136 |
96 |
Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. |
Medical College of Ohio |
12036367 |
46 |
Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. |
University of Montpellier |
22249122 |
9 |
Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imaging. |
Lehigh University |
21688787 |
295 |
New, potent, selective, and short-acting peptidic V1a receptor agonists. |
Ferring Research Institute |
21605973 |
69 |
Potent and selective oxindole-based vasopressin 1b receptor antagonists with improved pharmacokinetic properties. |
Abbott Laboratories |
21601454 |
26 |
Identification and optimisation of novel sulfonamide, selective vasopressin V1B receptor antagonists. |
Msd |
21596563 |
33 |
Synthesis and SAR studies of novel 2-(6-aminomethylaryl-2-aryl-4-oxo-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists. |
Msd |
21428295 |
43 |
Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors. |
University of Montpellier |
21353540 |
55 |
Synthesis and SAR studies of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists. |
Msd |
20550119 |
96 |
Oral oxytocin antagonists. |
Drugmoldesign |
20719508 |
26 |
Identification and optimization of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V3 (V1b) receptor antagonists. |
Ligand Pharmaceuticals |
18778939 |
23 |
Triazole oxytocin antagonists: identification of aryl ether replacements for a biaryl substituent. |
Pfizer |
31022340 |
101 |
Discovery of Potent, Selective, and Short-Acting Peptidic V |
Ferring Research Institute |
30896946 |
36 |
Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors. |
Tohoku University and Department of Pharmaceutical Sciences |
31229420 |
21 |
Synthesis of oxytocin derivatives lipidated via a carbonate or carbamate linkage as a long-acting therapeutic agent for social impairment-like behaviors. |
Kanazawa University |
10197974 |
22 |
Fluorescent pseudo-peptide linear vasopressin antagonists: design, synthesis, and applications. |
University of Montpellier |
31223461 |
56 |
Discovery of SHR1653, a Highly Potent and Selective OTR Antagonist with Improved Blood-Brain Barrier Penetration. |
Shanghai Hengrui Pharmaceutical |
31850759 |
24 |
Engineering a Potent, Long-Acting, and Periphery-Restricted Oxytocin Receptor Agonist with Anorexigenic and Body Weight Reducing Effects. |
Calibr At The Scripps Research Institute |
30098866 |
30 |
Novel, potent, selective and brain penetrant vasopressin 1b receptor antagonists. |
Abbvie Deutschland |
30199637 |
172 |
LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
Umr7200 Cnrs/Universit£ |
29602673 |
49 |
Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs. |
Imperial College |
26469307 |
7 |
Phosphorylation of Capsaicinoid Derivatives Provides Highly Potent and Selective Inhibitors of the Transcription Factor STAT5b. |
University of Leipzig |
16302795 |
36 |
Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. |
Merck Frosst Centre For Therapeutic Research |
1874734 |
53 |
The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. |
Laboratoires Glaxo |
9216835 |
30 |
Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere. |
Boehringer Ingelheim (Canada) |